Q1 Earnings Estimate for CLPT Issued By B. Riley

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) - Stock analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of ClearPoint Neuro in a report released on Friday, November 8th. B. Riley analyst K. Bauser anticipates that the company will post earnings of ($0.15) per share for the quarter. B. Riley currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for ClearPoint Neuro's current full-year earnings is ($0.65) per share. B. Riley also issued estimates for ClearPoint Neuro's Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.14) EPS and Q4 2025 earnings at ($0.14) EPS.

Separately, Lake Street Capital upped their price target on shares of ClearPoint Neuro from $11.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, August 27th.

ClearPoint Neuro Stock Performance

ClearPoint Neuro stock traded up $0.03 during midday trading on Monday, hitting $11.68. 171,980 shares of the company's stock were exchanged, compared to its average volume of 186,191. The company has a market cap of $322.32 million, a PE ratio of -16.88 and a beta of 1.10. ClearPoint Neuro has a 12 month low of $4.45 and a 12 month high of $14.13. The firm has a 50-day moving average of $12.14 and a two-hundred day moving average of $8.84.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its position in shares of ClearPoint Neuro by 23,048.0% during the 1st quarter. Russell Investments Group Ltd. now owns 46,296 shares of the company's stock valued at $315,000 after acquiring an additional 46,096 shares during the period. CM Management LLC increased its position in shares of ClearPoint Neuro by 87.5% in the first quarter. CM Management LLC now owns 375,000 shares of the company's stock valued at $2,550,000 after buying an additional 175,000 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of ClearPoint Neuro by 7.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 24,867 shares of the company's stock valued at $170,000 after buying an additional 1,813 shares in the last quarter. AWM Investment Company Inc. acquired a new position in shares of ClearPoint Neuro during the 1st quarter worth approximately $894,000. Finally, Legato Capital Management LLC raised its position in ClearPoint Neuro by 21.6% during the second quarter. Legato Capital Management LLC now owns 158,968 shares of the company's stock worth $857,000 after acquiring an additional 28,227 shares during the period. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.